Business Context and Reporting Period
This Form 6-K filing by Iris Energy Limited (dba IREN) covers the month of March 2024, with a specific reporting date of March 21, 2024. The document details updates to the Company's At Market Issuance Sales Agreement regarding the sale of its ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital raising activities.
- Aggregate Offering Price: Increased to $500,000,000.
- Shares Sold to Date: $261,471,363 (as of March 15, 2024).
- Remaining Capacity: Approximately $238,528,637 available under the updated agreement.
Material Changes
On March 21, 2024, the Company executed two significant changes to its existing Sales Agreement dated September 13, 2023:
- New Sales Agents: Added Canaccord Genuity LLC, Citigroup Global Markets Inc., and Macquarie Capital (USA) Inc. to the existing roster of agents (B. Riley Securities, Inc., Cantor Fitzgerald & Co., and Compass Point Research & Trading, LLC).
- Offering Size Increase: Filed a new prospectus supplement increasing the aggregate offering price by $200,000,000, raising the total limit from $300,000,000 to $500,000,000.
Guidance, Outlook, and Risks
The filing contains no management commentary on operational outlook, guidance, or specific risks beyond standard securities law disclaimers. It notes that sales are subject to the lesser of the amount registered on the effective Form F-3 registration statement and the amount authorized by the Board of Directors. The Company retains the ability to further increase the amount of shares sold under the agreement terms.
Investor Verification Checklist
- Verify the current market price of IREN ordinary shares to assess the dilution impact of the remaining ~$238.5 million offering capacity.
- Review the effective Form F-3 registration statement (File No. 333-274500) to confirm the total number of shares registered.
- Monitor future filings for the actual volume of shares sold under the expanded $500 million program.
- Check for any subsequent Board authorizations that may further adjust the sales limits.